<DOC>
	<DOC>NCT01921478</DOC>
	<brief_summary>This retrospective, multi-centre, observational study will assess the daily practice patterns and outcomes of the management of rheumatoid arthritis in patients treated with RoActemra/Actemra (tocilizumab). No actual patient will be enrolled in this study; data will be collected from medical records.</brief_summary>
	<brief_title>A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;=18 years of age Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 &gt;=5.1 Inadequate responder to at least 2 nonbiological DMARDs Absence of documented erosions at start of RoActemra/Actemra treatment Received RoActemra/Actemra treatment for at least 6 months Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit Contraindications for treatment with RoActemra/Actemra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>